Progrès thérapeutiques récents dans le mésothéliome malin primitif de la plèvre

Incidence of malignant pleural mesothelioma will rise until 2030–2040 because the elapsed time between exposure and diagnostic is up to several decades

M.-A. Mahé

2005

Scholarcy highlights

  • Incidence of malignant pleural mesothelioma will rise until 2030–2040 because the elapsed time between exposure and diagnostic is up to several decades
  • Prognosis remains very poor with median survival less than one year and five-year survival not exceeding 5%
  • Despite various growth factors and their receptors are involved in malignant mesothelioma, first clinical trials of targeted therapies reported poor results
  • As compared to bronchial carcinoma, inclusion of patients in clinical trials is the only way to somewhat improve results

Need more features? Save interactive summary cards to your Scholarcy Library.